Relationship between HIV-1 viral load and continued drug use in untreated infected injection drug users

Addiction Biology

Volumn 4, Issue 2, 1999, Pages 197-202

  Carrieri, Maria Patrizia ^a,f   Tamalet, Catherine ^b   Vlahov, David ^c   Yahi, Nouara ^b   Chesney, Margaret ^d   Moatti, Jean Paul ^e  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b TIMONE HOSPITAL   (France)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INSTITUT PAOLI CALMETTES   (France)

^f UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIAMORPHINE; MONOCLONAL ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; DEVICE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG USE; FEMALE; FRANCE; HEALTH CARE ACCESS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTCOMES RESEARCH; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; QUESTIONNAIRE; SELF INJECTION; SELF REPORT; SEROLOGY; STATISTICAL ANALYSIS; T LYMPHOCYTE; VIRUS LOAD;

EID: 0032928982     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/13556219971704     Document Type: Article

References (34)

1. Biggar RJ and the International Registry of Seroconverters. AIDS incubation in 1891 HIV seroconverters from different exposure groups. AIDS 1990;4:1059-66.
2. Des Jarlais DC, Friedman SR, Marmor L et al. Development of AIDS, HIV seroconversion and potential cofactor for T4 cell loss in a cohort of intravenous drug users. AIDS 1987;1:105-11.
3. Pezzotti P, Phillips A, Dorrucci M et al. Category of exposure to HIV and age in progression to AIDS: longitudinal study of 1119 people with known date of seroconversion. Br Med J 1996;313:583-6.
4. Galai N, Vlahov D, Margolik JB, Chen K, Graham NMH, Muñoz A. Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men. J AIDS 1995;8:66-74.
5. Alcabes P, Muñoz A, Vlahov D, Friedland G. Maturity of immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users. Ann Epidemiol 1994;4:17-26.
6. + lymphocytes in human immunodeficiency virus-positive homosexual men and injecting drug users. Arch Intern Med 1994;154:869-75.
7. Prins M, Veugelers PJ. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study. AIDS 1997;11:621-31.
8. Ronald PJM, Robertson JR, Elton RA. Continued drug use and other cofactors for progression to AIDS among injecting drug users. AIDS 1994;8: 339-43.
9. Weber R, Lederberger B, Opravil M, Siegenthaler W, Luthy R. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a maintenance treatment with Methadone. Br Med J 1990;301:1362-5.
10. Muñoz A, Vlahov D, Solomon L et al. Prognostic indicators for development of AIDS among intravenous drug users. J AIDS 1992;5:694-700.
11. Selwyn PA, Alcabes P, Hartel D et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992;327: 1697-703.
12. Alcabes P, Selwyn PA, Davenny K et al. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. AIDS 1994;8: 107-15.
13. Margolik JB, Muñoz A, Vlahov D, 1994; et al. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. J Am Med Assoc 1992;267:1631-6.
14. Crum RM, Galai N, Cohn S, Celentano DD, Vlahov D Alcohol use and T-lymphocyte subsets among injection drug users with HIV-1 infection: a prospective analysis. Alcohol Clin Exp Res 1996; 20:364-71.
15. + lymphocyte decline among HIV-1 infected injecting drug users. AIDS 1997;11:1255-62.
16. Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH Jr. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 1990;4: 869-73.
17. Peterson PK, Gekker G, Schut R, Hu S, Balfour HH Jr, Chao CC. Enhancement of HIV-1 replication by opiates and cocaine: the cytokine connection. Adv Exp Med Biol 1993;335:181-8.
18. Donahoe RM, Falek A, Madden JJ et al. Effects of cocaine and other drugs of abuse on immune function. Adv Exp Med Biol 1991;288:143-50.
19. Brown SM, Stimmel B, Taub RN, Kochwa S, Rosenfield RE. Immunologic dysfunction in heroin addicts. Arch Intern Med 1974;134:1001-6.
20. Perez-Castrillon JL, Perez-Arellano JL, Garcia-Palomo JD Garcia-Palomo JD, Jimenez-Lopez A, De Castro S. Opioids depress in vitro human monocyte chemotaxis. Immunopharmacology 1992;23:57-61.
21. Schweitzer C, Keller F, Schmitt MP et al. Morphine stimulates HIV replication in primary cultures of human Kupffer cells. Res Virol 1991;142: 189-95.
22. Carr DJJ, Serou M. Exogenous and endogenous opioids as biological response modifiers. Immunopharmacology 1995;31:59-71.
23. Stoll-Keller F, Schmitt C, Thumann, Schmitt MP, Caussin C, Kirn A. Effect of morphine on purified human blood monocytes. Modifications of properties involved in antiviral defences. Int J Immunopharmacol 1997;19:95-100.
24. Squinto SP, Mondal D, Block AL, Prakash O. Morphine-induced transactivation of HIV-1 LTR in human neuroblastoma cells. AIDS Res Human Retroviruses 1990;6:1163-8.
25. Solomon L, Vlahov D, Astemborski J, Galai N, Graham N. Factors associated with initiation of Zidovudine in a cohort of IDUs. J Drug Issues 1995;25:225-33.
26. Crandall SC, Coleman R. AIDS-related discrimination and the disruption of social relationships. J Soc Pers Relation 1992;9:163-77.
27. Phillips AN, Sabin CA, Mocroft A. Active drug injecting and progression of HIV infection. AIDS 1994;8:385-6.
28. Moatti J-P, Souville M, Obadia Y et al. Ethical dilemmas in care for HIV infection among French general practitioners. Health Policy 1995;31: 197-210.
29. Green G, Platt S. Fear and loathing in health care settings reported by people with HIV. Sociol Health Illnesses 1997;19:70-92.
30. Donovan RM, Bush CE, Markowitz NP, Baxa DM, Saravolatz LD. Changes in viral load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis 1996;174:401-3.
31. Farzadegan H, Levy D, Astemborski J, Saah AJ, Vlahov D, Graham NMH. The effect of gender race injecting drug use and disease stage on infectious HIV-1 viral burden among IDUs and gay men. XI International Conference on AIDS, Vancouver 1996 [abstract WeC 3422].
32. Phillips AN, Eron JJ, Bartlett JA et al. and the North American Lamivudine HIV Working Group. HIV-1 RNA levels and the development of clinical disease. AIDS 1996;10:859-65.
33. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
34. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. STD 1992;19:61-77.